Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). IDEAYA Biosciences's share price for the quarter that ended in Mar. 2026 was $33.32. IDEAYA Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 87.9 Mil. Therefore, IDEAYA Biosciences's market cap for the quarter that ended in Mar. 2026 was $2,927.4 Mil.
IDEAYA Biosciences's quarterly market cap
increased
from Sep. 2025 ($2,385.4 Mil) to Dec. 2025 ($3,035.1 Mil) but then
declined
from Dec. 2025 ($3,035.1 Mil) to Mar. 2026 ($2,927.4 Mil).
IDEAYA Biosciences's annual market cap
declined
from Dec. 2023 ($2,314.1 Mil) to Dec. 2024 ($2,223.2 Mil) but then
increased
from Dec. 2024 ($2,223.2 Mil) to Dec. 2025 ($3,035.1 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. IDEAYA Biosciences's Enterprise Value for Today is $2,852.2 Mil.
IDEAYA Biosciences (NAS:IDYA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
IDEAYA Biosciences Market Cap Related Terms
IDEAYA Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IDEAYA Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
IDEAYA Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a Market Cap of $3,494.8 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IDEAYA Biosciences and its competitors. According to the industry distribution chart, IDEAYA Biosciences ranks #112 out of 1430 companies in the Biotechnology industry, placing it in the top 7.8%.
Is IDEAYA Biosciences' Market Cap too high?
IDEAYA Biosciences' current Market Cap is $3,494.8 Mil. The Biotechnology industry median Market Cap is 117.26. IDEAYA Biosciences' value of $3,494.8 Mil is 2880.3% above this industry median. Based on the distribution chart, IDEAYA Biosciences ranks #112 out of 1430 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IDEAYA Biosciences has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Market Cap compare to MLYS and TARS?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #112 out of 1430 companies for Market Cap. This places IDEAYA Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.26. IDEAYA Biosciences' value of $3,494.8 Mil is 2880.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEAYA Biosciences's current Market Cap of $3,494.8 Mil is 2880.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on IDEAYA Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current Market Cap is $3,494.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $214.33, compared to a current price of $36.30 — trading 83.1% below its estimated fair value. The current Market Cap is $3,494.8 Mil and 2880.3% above the Biotechnology industry median of 117.26. IDEAYA Biosciences' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Market Cap is $3,494.8 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $36.30 is trading 83.1% below its estimated GF Value™ of $214.33.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
Market Cap: $3,494.8 Mil
GF Value™: $214.33 vs. price of $36.30 (83.1% below fair value)
Industry Position: 2880.3% above the Biotechnology median (#112 of 1430)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
55GF Score
Get the complete analysis for IDYA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
